News Image

Why NASDAQ:PGNY Is a Promising High-Growth Stock in the Midst of Consolidation.

By Mill Chart

Last update: Mar 25, 2024

Growth investors are on the lookout for stocks displaying robust revenue and EPS growth. In this analysis, we'll assess whether PROGYNY INC (NASDAQ:PGNY) aligns with growth investing criteria, especially as it consolidates and signals a possible breakout. As always, investors should conduct their own research, but PROGYNY INC has surfaced on our radar for growth with base formation, warranting further examination.

Evaluating Growth: NASDAQ:PGNY

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:PGNY scores a 9 out of 10:

  • The Earnings Per Share has grown by an impressive 106.67% over the past year.
  • PGNY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 97.89% yearly.
  • The Revenue has grown by 38.35% in the past year. This is a very strong growth!
  • PGNY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.52% yearly.
  • Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.83% on average per year.
  • The Revenue is expected to grow by 18.19% on average over the next years. This is quite good.

Understanding NASDAQ:PGNY's Health Score

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:PGNY has received a 9 out of 10:

  • An Altman-Z score of 13.21 indicates that PGNY is not in any danger for bankruptcy at the moment.
  • PGNY has a better Altman-Z score (13.21) than 96.55% of its industry peers.
  • PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • PGNY has a Current Ratio of 3.44. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
  • PGNY's Current ratio of 3.44 is amongst the best of the industry. PGNY outperforms 90.52% of its industry peers.
  • A Quick Ratio of 3.44 indicates that PGNY has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 3.44, PGNY belongs to the best of the industry, outperforming 90.52% of the companies in the same industry.

Looking at the Profitability

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:PGNY scores a 7 out of 10:

  • With an excellent Return On Assets value of 8.20%, PGNY belongs to the best of the industry, outperforming 91.38% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 11.22%, PGNY is in the better half of the industry, outperforming 77.59% of the companies in the same industry.
  • PGNY has a better Return On Invested Capital (9.57%) than 88.79% of its industry peers.
  • The 3 year average ROIC (8.61%) for PGNY is below the current ROIC(9.57%), indicating increased profibility in the last year.
  • The Profit Margin of PGNY (5.70%) is better than 86.21% of its industry peers.
  • With a decent Operating Margin value of 5.71%, PGNY is doing good in the industry, outperforming 70.69% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PGNY has grown nicely.
  • In the last couple of years the Gross Margin of PGNY has grown nicely.

How do we evaluate the setup for NASDAQ:PGNY?

ChartMill incorporates a Setup Rating in its analysis, which measures the extent of consolidation in a stock over recent days and weeks. This rating, ranging from 0 to 10, is updated daily and takes into account multiple short-term technical indicators. The current setup rating for NASDAQ:PGNY is 8:

PGNY has a bad technical rating, but it does show a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is very little resistance above the current price. There is a support zone below the current price at 37.02, a Stop Loss order could be placed below this zone.

More Strong Growth stocks can be found in our Strong Growth screener.

Check the latest full fundamental report of PGNY for a complete fundamental analysis.

Our latest full technical report of PGNY contains the most current technical analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

PROGYNY INC

NASDAQ:PGNY (4/18/2024, 7:13:59 PM)

Premarket: 31.77 -0.11 (-0.35%)

31.88

-0.87 (-2.66%)

PGNY News

News Image15 days ago - ProgynyProgyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

The leading benefits solution and largest infertility advocacy non-profit will host a series of events aimed at raising awareness for the millions of individuals facing family building challenges

News Image15 days ago - ProgynyProgyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

The leading benefits solution and largest infertility advocacy non-profit will host a series of events aimed at raising awareness for the millions of...

News Imagea month ago - ProgynyProgyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits...

News Imagea month ago - InvestorPlaceThe 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024

Wager on these top undervalued mid-cap stocks, effectively blending growth and value, with a remarkable broader-market performance in 2023.

News Imagea month ago - BusinessInsiderThe 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Wagering on mid-cap stocks can potentially unlock investment treasures typicall...

News Imagea month ago - ProgynyProgyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits...

News Image2 months ago - Seeking AlphaProgyny announces $100M share repurchase program (NASDAQ:PGNY)

Progyny (PGNY) approves $100 million share repurchase program funded by available cash balances.

News Image2 months ago - ProgynyProgyny, Inc. Announces Share Repurchase Program
News Image2 months ago - ProgynyProgyny, Inc. Announces Share Repurchase Program

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits...

News Image2 months ago - Market News VideoWednesday Sector Laggards: Hospital & Medical Practitioners, Oil & Gas Refining & Marketing Stocks
News Image2 months ago - ProgynyProgyny, Inc. Announces Fourth Quarter 2023 Results
News Image2 months ago - ProgynyProgyny, Inc. Announces Fourth Quarter 2023 Results

Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% GrowthAchieves 49% Growth in Adjusted EBITDA to Record $187.1 MillionIssues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint

PGNY Links
Follow us for more